Skip to main content Accessibility help
×
Home

Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal

  • G. GONÇALVES (a1), J. FRADE (a1) (a2), M. S. J. NASCIMENTO (a3), J. R. MESQUITA (a4) and C. NUNES (a5)...

Summary

In Portugal, the recommended age for the second dose of MMR (MMR2) was changed from 10–13 years to 5–6 years for those born in 1994 and afterwards. This study aimed to assess if MMR schedule and time elapsed from the last dose are associated with the concentration of rubella and mumps IgG antibodies. Three Portuguese birth cohorts (convenience samples) were selected for this study (66, 59 and 41 participants born respectively in 1990–1993, 1994–1995 and 2001–2003). Geometric mean concentrations (GMC) for mumps IgG were respectively 36, 30 and 38 RU/ml (P = 0·236) and for rubella IgG were 18, 20 and 17 IU/ml (P = 0·641). For both specific antibodies, no differences were observed with time since MMR2. Receiving MMR2 at 5–6 or 10–13 years was not associated with concentration of both antibodies. The GMC of rubella IgG was lower in males (P = 0·029). Taking into account previous evidence and the logistics needed to change vaccination schedules, it seems reasonable that sustaining very high coverage with two doses of MMR is currently the most pragmatic way to control mumps and rubella rather than any changes to the schedule.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: Professor G. Gonçalves, Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Rua de Jorge Viterbo Ferreira no. 228, 4050-313 Porto, Portugal. (Email: aggoncalves@icbas.up.pt)

References

Hide All
1. Best, JM, Reef, S. WHO immunological basis for immunization series . Module 11: Rubella. Geneva, Switzerland: World Health Organization, 2008.
2. Cutts, FT, Lessler, J, Metcal, CJE. Measles elimination progress: challenges and implication for rubella control. Expert Review Vaccines 2013; 12: 917932.
3. Hinman, AR, et al. Economic analyses of rubella and rubella vaccines: a global review. Bulletin of the World Health Organization 2002, 80: 264270.
4. Mclean, HQ, Hickman, CJ, Seward, JF. WHO immunological basis for immunization series . Module 16: Mumps. Geneva, Switzerland: World Health Organzation, 2010.
5. World Health Organization. Mumps virus vaccines. WHO position paper. Weekly Epidemiological Record 2007; 82: 4960.
6. Koplan, JP, Preblud, SR. A benefit-cost analysis of mumps vaccine. American Journal of Diseases of Children 1982; 136: 362364.
7. White, CC, Koplan, JP, Oreinstein, WA. Benefits, risks and costs of immunization for measles, mumps and rubella. American Journal of Public Health 1985; 75: 739744.
8. Bart, KJ, Orenstein, WA, Hinman, AR. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles. Developments in Biological Standardization 1986; 65: 4552.
9. LeBaron, CW, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. Journal of Infectious Diseases 2009; 199: 552560.
10. European Centre for Disease Prevention and Control (ECDC). Vaccine schedule. Recommended immunisations for measles. Stockholm: ECDC, 2005 (http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx). Accessed October 2015.
11. Moss, WJ, Scott, S. WHO immunological basis for immunization series . Module 9: Measles. Geneva, Switzerland: World Health Organization, 2009.
12. LeBaron, CW, et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. Journal of Infectious Diseases 2009; 200: 888899.
13. Kakoulidou, M, et al. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults. Vaccine 2013; 31: 711717.
14. Poethko-Müller, C, Mankertz, A. Seroprevalence of measles-, mumps- and rubella- specific IgG antibodies in German children and adolescents and predictors of seronegativity. PLoS ONE 2012; 7: e42867.
15. Davidkin, I, et al. Peristence of measles, mumps and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. Journal of Infectious Diseases 2008; 197: 950956.
16. Vandermeunlen, C, et al. Long-term persistence of antibodies after one or two doses of MMR vaccine. Vaccine 2007; 25: 66726676.
17. Gonçalves, G, et al. Levels of rubella antibody among vaccinated and unvaccinated Portuguese mothers and their newborns. Vaccine 2006; 24: 71427147.
18. Saldanha, MJ, Azevedo, A. Congenital rubella. Still with us [in Portuguese]. Acta Médica Portuguesa 1995; 8: 319322.
19. Gonçalves, G, Araújo, A, Cardoso, MLM. Outbreak of mumps associated with poor vaccine efficacy – Oporto, Portugal, 1996. Eurosurveillance 1998; 3: 119121.
20. Portuguese Health Ministry. Direcção-Geral da Saúde. Statutory notifications of infectious diseases 2009–2012, Volume I (http://www.dgs.pt/estatisticas-de-saude/estatisticas-de-saude/publicacoes/doencas-de-declaracao-obrigatoria-2009-2012-volume-i.aspx). Accessed March 2015.
21. Portuguese Health Ministry. Direcção-Geral da Saúde. National Plan for Measles Elimination (Guidelines Number: 006/2013 Date: 02/04/2013) (http://www.dgs.pt/documentos-e-publicacoes/programa-nacional-de-eliminacao-do-sarampo.aspx). Accessed March 2015.
22. Gonçalves, G, et al. High vaccine coverage in the north of Portugal. A strategy to assess and increase coverage. Eurosurveillance 2005; 10: 98102.
23. Gonçalves, G, et al. Persistence of measles antibodies, following changes in the recommended age at the second dose of MMR vaccine in Portugal. Vaccine 2015; 33: 50575063.
24. Gonçalves, G. Herd immunity: recent uses in vaccine assessment. Expert Review Vaccines 2008; 7: 14931506.
25. Gao, Z, et al. Models of strategies for control of rubella and congenital rubella syndrome-a 40 year experience from Australia. Vaccine 2013; 31: 691697.
26. Abrams, S, Beutels, P, Hens, N. Assessing mumps outbreak risk in highly vaccinated populations using spacial seroprevalence data. American Journal of Epidemiology 2014; 179: 10061017.

Keywords

Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal

  • G. GONÇALVES (a1), J. FRADE (a1) (a2), M. S. J. NASCIMENTO (a3), J. R. MESQUITA (a4) and C. NUNES (a5)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed